Literature DB >> 15728510

The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1.

Nicolas Molnarfi1, Nevila Hyka-Nouspikel, Lyssia Gruaz, Jean-Michel Dayer, Danielle Burger.   

Abstract

IFN-beta induces the production of secreted IL-1R antagonist (sIL-1Ra) without triggering synthesis of the agonist IL-1beta in human monocytes. This might account for its anti-inflammatory properties. Canonically, IFN-beta signals through activation of JAK/STAT pathway, although PI3K and MAPK have also been involved. In this study, the role of PI3K, MEK1, and STAT1 in IFN-beta-induced sIL-1Ra production is investigated in freshly isolated human blood monocytes. PI3K, but not MEK1 activation is essential for sIL-1Ra production in monocytes treated with IFN-beta, as demonstrated by using the respective inhibitors of PI3K and MEK1, Ly294002 and PD98059. The use of cycloheximide and actinomycin D shows that sIL-1Ra was an immediate early gene induced by IFN-beta and that PI3K was controlling sIL-1Ra gene transcription. Although both inhibitors of PI3K and MEK1 diminished the Ser(727) phosphorylation of STAT1 induced by IFN-beta, only Ly294002 inhibited sIL-1Ra production. Furthermore, the inhibition of STAT1-Ser(727) phosphorylation by Ly294002 did not affect STAT1 translocation, suggesting that STAT1 was not involved in sIL-1Ra gene induction. This was confirmed in monocytes that were transfected with small interfering RNA specifically targeting STAT1. Indeed, monocytes in which effective STAT1 gene knockdown was achieved were fully responsive to IFN-beta in terms of sIL-1Ra production. Taken together, the present data demonstrate that the induction of sIL-1Ra transcription and production by IFN-beta in human monocytes involved PI3K, but not STAT1 activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728510     DOI: 10.4049/jimmunol.174.5.2974

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.

Authors:  Rakel Carpintero; Karim J Brandt; Lyssia Gruaz; Nicolas Molnarfi; Patrice H Lalive; Danielle Burger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

2.  IFNβ and glatiramer acetate trigger different signaling pathways to regulate the IL-1 system in multiple sclerosis.

Authors:  Rakel Carpintero; Danielle Burger
Journal:  Commun Integr Biol       Date:  2011-01

3.  Toll-like receptor-mediated production of IL-1Ra is negatively regulated by GSK3 via the MAPK ERK1/2.

Authors:  Kunal Rehani; Huizhi Wang; Carlos A Garcia; Denis F Kinane; Michael Martin
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

4.  Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis.

Authors:  Abhisake Kole; JianPing He; Aymeric Rivollier; Danielle D Silveira; Kazuya Kitamura; Kevin J Maloy; Brian L Kelsall
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

Review 5.  Mammalian gut immunity.

Authors:  Benoit Chassaing; Manish Kumar; Mark T Baker; Vishal Singh; Matam Vijay-Kumar
Journal:  Biomed J       Date:  2014 Sep-Oct       Impact factor: 4.910

6.  Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway.

Authors:  Azusa Matsumoto; Tatsuki Ichikawa; Kazuhiko Nakao; Hisamitsu Miyaaki; Kumi Hirano; Masumi Fujimito; Motohisa Akiyama; Satoshi Miuma; Eisuke Ozawa; Hidetaka Shibata; Shigeyuki Takeshita; Hironori Yamasaki; Masanori Ikeda; Nobuyuki Kato; Katsumi Eguchi
Journal:  J Gastroenterol       Date:  2009-05-13       Impact factor: 7.527

Review 7.  The role of type I interferons in intestinal infection, homeostasis, and inflammation.

Authors:  Hyeseon Cho; Brian L Kelsall
Journal:  Immunol Rev       Date:  2014-07       Impact factor: 12.988

8.  Human TLR10 is an anti-inflammatory pattern-recognition receptor.

Authors:  Marije Oosting; Shih-Chin Cheng; Judith M Bolscher; Rachel Vestering-Stenger; Theo S Plantinga; Ineke C Verschueren; Peer Arts; Anja Garritsen; Hans van Eenennaam; Patrick Sturm; Bart-Jan Kullberg; Alexander Hoischen; Gosse J Adema; Jos W M van der Meer; Mihai G Netea; Leo A B Joosten
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-06       Impact factor: 11.205

9.  Overview of the biology of type I interferons.

Authors:  George D Kalliolias; Lionel B Ivashkiv
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

10.  TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage.

Authors:  F A Carvalho; J D Aitken; A T Gewirtz; M Vijay-Kumar
Journal:  Mucosal Immunol       Date:  2010-09-15       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.